Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277168 · ClinicalTrials.gov registry record · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT05277168: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co..
NCT05277168 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 83 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277168, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Jiangsu HengRui Medicine Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.
Primary Outcome
DLT is defined during the first cycle of the study treatment and assessed as certainly or at least possibly related to SHR-A1904 treatment.
Conditions Studied
Interventions
- DRUG SHR-A1904
Study Locations (20)
New South Wales
- Central Coast Local Health District - Gosford
- Sydney South West Private Hospital - Liverpool
- Scientia Clinical Research Ltd - Randwick
- Genesis Care North Shore - St Leonards
- Macquarie University - Sydney
- Westmead Hospital - Westmead
Other
- National Institute of Oncology, Arensia Research Clinic - Chisinau
- Dong-A University Hospital - Busan
- Chungbuk National University Hospital - Cheongju-si
- Ajou University Hospital - Gyeonggi-do
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Comprehensive Hematology Oncology - St. Petersburg
Louisiana
- LSU Health Sciences Center - New Orleans
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Rhode Island
- Rhode Island Hospital - Providence
South Carolina
- Prisma Health - Greenville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 1 |
What NCT05277168 shows while recruiting
NCT05277168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SHR-A1904 is the first listed.
NCT05277168 names 20 study sites across 11 states, led by New South Wales, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05277168 about?
NCT05277168 is a clinical study titled "A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors". The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK)...
What is the current status of trial NCT05277168?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2022-05-30. Estimated completion is 2026-05-30.
What conditions does trial NCT05277168 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05277168?
The interventions under investigation include: SHR-A1904 (DRUG).
Who is sponsoring clinical trial NCT05277168?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277168 being conducted?
This trial has 20 study locations across Florida, Louisiana, Ohio, Rhode Island, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05277168's enrollment target sits among peer trials
83 88th of 144 higher than 57 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05419089 · 83 participants · Phase 2
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI